Molecular mechanisms and therapeutic interventions in sarcopenia.
10.1016/j.afos.2017.08.098
- Author:
Sung Sup PARK
1
;
Eun Soo KWON
;
Ki Sun KWON
Author Information
1. Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. kwonks@kribb.re.kr
- Publication Type:Review
- Keywords:
Mechanisms;
Therapy;
Skeletal;
Aging;
Sarcopenia
- MeSH:
Aging;
Apoptosis;
Atrophy;
Autophagy;
Classification;
Hypertrophy;
MicroRNAs;
Muscle Fibers, Skeletal;
Neuromuscular Junction;
Risk Factors;
Sarcopenia*;
Stem Cells
- From:Osteoporosis and Sarcopenia
2017;3(3):117-122
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sarcopenia is the degenerative loss of muscle mass and function with aging. Recently sarcopenia was recognized as a clinical disease by the International Classification of Disease, 10th revision, Clinical Modification. An imbalance between protein synthesis and degradation causes a gradual loss of muscle mass, resulting in a decline of muscle function as a progress of sarcopenia. Many mechanisms involved in the onset of sarcopenia include age-related factors as well as activity-, disease-, and nutrition-related factors. The stage of sarcopenia reflecting the severity of conditions assists clinical management of sarcopenia. It is important that systemic descriptions of the disease conditions include age, sex, and other environmental risk factors as well as levels of physical function. To develop a new therapeutic intervention needed is the detailed understanding of molecular and cellular mechanisms by which apoptosis, autophagy, atrophy, and hypertrophy occur in the muscle stem cells, myotubes, and/or neuromuscular junction. The new strategy to managing sarcopenia will be signal-modulating small molecules, natural compounds, repurposing of old drugs, and muscle-specific microRNAs.
